Rajan founded Ellipses Pharma in 2018 with Professor Sir Chris Evans, to focus on the development of innovative cancer medicines and treatments, with the mission of making them available to patients at unprecedented speed.

At Ellipses he has developed a differentiated model in drug development that combines unbiased vetting of potential drug candidates to de-risk initial drug selection and trial design with an uninterrupted flow of capital to minimise the time it takes to advance drugs through the clinical trial process and reach patients.

Having held positions across the industry, as a surgeon, investor and chief executive, Rajan has spent nearly 20 years building and leading successful life science businesses at the frontier of the sector.

Rajan graduated from Cambridge University with undergraduate and postgraduate degrees in Medical Sciences and is a member of the Royal College of Surgeons of England.

David has been Chief Financial Officer at Ellipses since its early stages and is also a Director on its Board.

As a central member of the executive team, he drives the company’s growth and helps to set its strategy, as well as taking on key responsibilities in funding and business development.

David has extensive experience as a CFO within the life sciences industry. He began his career at PricewaterhouseCoopers where he qualified as a chartered accountant, before holding CFO and Group Financial Controller positions at several life sciences companies. A personal highlight was his steering of Biotie Therapies through its listing on NASDAQ, as its CFO. More recently, he has served on the board of AIM-listed Alliance Pharmaceuticals, including currently as its Non-Executive Chairman.

David holds a degree in Chemistry from the University of Oxford.

Tobi is responsible for the clinical development of the drugs in Ellipses’ pipeline. He leads clinical strategy, coordinates the drug development teams to deliver the clinical programmes and is an ambassador for our Scientific Affairs Group.

Over the course of his career, Tobi has worked on over 300 early-stage clinical trials, with several of these trials providing the compounds that have gone on to become the new standard of care.

A Medical Oncologist by training, Tobi is a practicing clinician having begun his early career as an oncologist in Bremen, Germany and then at the Royal Marsden Hospital in London, before becoming a team leader in Clinical Drug Development at the University of New South Wales, Australia. He has

spent over a decade as a Professor at University College London, and most recently was the Executive Medical Director at the Sarah Cannon Research Institute. He holds a PhD from the Medical School of Hanover.

Martin is an expert in drug development and manufacturing and has played a pivotal role in bringing thirteen drugs to market to date. His broad experience across the pharmaceutical industry started within big pharma at Aventis, includes eight years at Shire Pharmaceuticals, where he was a Senior Director of Product Development, and more recently as Global Head of Product Development and Manufacturing at HUYA Bioscience.

At Ellipses, Martin leads the non-clinical and preclinical development arms of the organisation, working in conjunction with the clinical development arm to progress Ellipses’ exciting portfolio of oncology assets.

Martin graduated with a degree in Applied and Analytical Chemistry from Staffordshire University and has a post-graduate certificate in management studies.